Why CollPlant Biotechnologies Ltd.’s (CLGN) Stock Is Down 32.05%
As of Friday, May 30, CollPlant Biotechnologies Ltd.’s CLGN share price has dipped by 32.05%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Commentary & Analysis
Why CollPlant Biotechnologies Ltd.’s (CLGN) Stock Is Down 31.28%
As of Friday, May 30, CollPlant Biotechnologies Ltd.’s CLGN share price has dipped by 31.28%, which has investors questioning if this is right time to buy.Omar Beirat
Is Collplant Biotechnologies Ltd - ADR (CLGN) Stock a Good Investment?
Learn more about Collplant Biotechnologies Ltd - ADR's (CLGN) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Issac Deleon
Financial Summary
| Share Statistics | CLGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.6 | $242.6 | 5% |
|
| Shares Out (Mil) | 1.4 | 54.0 | 6% |
|
| Institutional Ownership | 18.2% | 93.1% | 9% |
|
| Float (Mil) | 1.1 | 41.4 | 3% |
|
| Beta | 0.76 | 0.95 | 45% |
|
| Avg Daily Volume (000s) | 43 | 633 | 27% |
|
| Price Change (52-week) |
(84.7%) | 50.0% | 7% |
|
| Growth | CLGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (17.0%) | 12.5% | 3% |
|
| Net Income (5yr) | (14.7%) | (10.1%) | 26% |
|
| EPS (5yr) | (2.3%) | 15.8% | 28 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (51.5%) | (15.7%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CLGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 1% |
|
| Net Income (TTM) (Mil) | ($13) | ($44) | 27% |
|
| EPS (TTM) | ($9.321) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($34) | 19% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $2 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 19% |
|
| Enterprise Value (Q1) (Mil) | $7 | $177 | 6% |
|
| Valuation | CLGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.72 | 2.33 | 47% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CLGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (321.7%) | 67.3% | 1% |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (74.1%) | (47.6%) | 8% |
|
| ROE | (105.7%) | (54.9%) | 9% |
|
| Liabilities to Assets | 59.1% | 29.3% | 53% |
|
| F-Score | 1 | 3 | 1% |
|
CollPlant Biotechnologies Ltd. did not pass any screens on 10/9/2026.
